Advanced Search
Current and Breaking News for Professionals, Consumers and Media




News : National Author: Staff Editor Last Updated: Sep 7, 2017 - 10:06:33 PM



Reversing the Effects of Pulmonary Fibrosis with a microRNA Mimic

By Staff Editor
Sep 22, 2014 - 12:55:09 PM



Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust


Email this article
 Printer friendly page

(HealthNewsDigest.com) - New Haven, Conn.-Yale University researchers are studying a potential new treatment that reverses the effects of pulmonary fibrosis, a respiratory disease in which scars develop in the lungs and severely hamper breathing.

The treatment uses a microRNA mimic, miR-29, which is delivered to lung tissue intravenously. In mouse models, miR-29 not only blocked pulmonary fibrosis, it reversed fibrosis after several days.

The findings were published Sept. 19 in the journal EMBO Molecular Medicine.

"The mimic, when injected into the blood, goes to the lung and it has a sustained effect. We are very impressed that it can reverse fibrosis, not only prevent it," said Naftali Kaminski, M.D., a professor at Yale School of Medicine and section chief of pulmonary, critical care, and sleep medicine. He is a corresponding author of the study.

The research is a collaboration between Yale and miRagen Therapeutics, a pharmaceutical company based in Boulder, Colo. The company had developed miR-29 previously as a possible therapy for cardiac disease. Kaminski, whose group pioneered research in microRNA in lung fibrosis, saw the potential for use of miR-29 in pulmonary fibrosis, as did Eva van Rooij, the scientist who discovered the role for miR-29 in cardiac fibrosis and is a senior co-author on the paper.

"I'm particularly excited about working with this microRNA," said van Rooij, who now is at the Hubrecht Institute in the Netherlands. "All evidence points to it being a master regulator of fibrosis."

The next step, Kaminski said, will be to begin evaluating miR-29 as a therapeutic for human Idiopathic Pulmonary Fibrosis (IPF). Once considered a rare disease, IPF now affects more than 200,000 people in the United States, where about 30,000 people die from IPF every year. The median survival from diagnosis is 3-5 years, and despite recent promising advances there is no intervention that reverses the disease.


###

For ad/promo rates, call Mike McCurdy at 877-634-9180 or email at [email protected]  We have over 7,000 journalists who are subscribers.

 



Top of Page

HealthNewsDigest.com

National
Latest Headlines


+ Adolescent Females Were Especially Vulnerable to Mental Health Impact of Pandemic-Related School Closings
+ Alarming Prevalence of Smell, Taste Loss During COVID’s Delta Surge
+ Correct Posture in Real Time with the Help of Machine Learning
+ Get a COVID-19 Booster
+ What’s In The Water?
+ Harmless Cells Turn Into Ruthless Trained Killers
+ Stress Also Among Wild Life
+ Silk Improves Function of Masks
+ Drug That Lowers Blood Sugar Also Reduces Blood Vessel Dysfunction
+ Gastritis: Its Symptoms



Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions